Milrinone

Indications


Pharmacology

  • Phosphodiesterase Type 3 Inhibitor (see Phosphodiesterase Type 3 Inhibitors, [[Phosphodiesterase Type 3 Inhibitors]]): inhibits cAMP degradation
    • Increased Myocardial Contractility
    • Decreased Pulmonary Vascular Resistance (PVR)
    • Vasodilation (Afterload Reduction)

Metabolism

  • xxx

Administration

  • xxxx

Dose Adjustment

  • Hepatic
  • Renal

Adverse Effects

Cardiovascular Adverse Effects

Other Adverse Effects

  • xxx

References

  • xxxx